1. The supernatant obtained by centrifugation of a rat liver homogenate at 10000Og for 1 h contained a heat-labile macromolecular inhibitor of the thrombin-fibrinogen reaction. 2. The inhibitor was purified to electrophoretic homogeneity by repeated preparative polyacrylamide disc electrophoresis. Inhibition was observed with purified inhibitor equivalent to about 1 jig of protein/ml. 3. The inhibitor had a pI of 3.50-3.75, a molecular weight (from sodium dodecyl sulphate-polyacrylamide-gel electrophoresis) of 72000±3000 and was inactivated by p-hydroxymercuribenzoate or 5,5'-dithiobis-(2-nitrobenzoic acid). 4. Kinetic studies revealed a non-competitive inhibition, with the inhibitor probably acting on the thrombin-fibrinogen complex.
Studies on the subcellular localization of the coagulation factor VII (Gaarder & Prydz, 1967 revealed the presence of an inhibitor of blood coagulation in the 100000g supernatant from perfused rat liver. We report here the purification of this inhibitor and some studies of its mode of action.
Materials and Methods Special chemicals and biochemicals
Trypsin was from Difco, Detroit, Mich., U.S.A.; 5,5'-dithiobis-(2-nitrobenzoic acid) was from Aldrich, Milwaukee, Wis., U.S.A.; p-hydroxymercuribenzoate and dithioerythritol were from Sigma Chemical Co., St. Louis, Mo., U.S.A.; heparin was from Apotekernes Laboratorium, Oslo, Norway; p-tosyl-L-arginine methyl ester was from Nutritional Biochemicals, Cleveland, Ohio, U.S.A.
Substrates for testing proteolytic activity Casein (Eastman Kodak, Rochester, N.Y., U.S.A.) was dissolved in 0.075M-NaCl in 0.025M-sodium phosphate buffer, pH7.6, heated to 85-90°C, dialysed against double-distilled water and diluted with VBS mnedium,* pH7.4, to E280 0.7. Other substrates were ovalbumin (Signa), human albumin (grade III; Sigma), azo-fibrinogen (bovine; Calbiochem A.-G., Lucerne, Switzerland) andazo-collagen (Calbiochem), all at 1 mg/ml in VBS medium.
Coagulation reagents
Bovine thrombin (Topostasine; Hoffmann-La Roche and Co. Ltd., Basle, Switzerland) was dis-* Abbreviation: VBS medium, veronal-buffered saline (9vol. of 0.15M-NaCI, lvol. of 28.5mM-veronal buffer) (Owren, 1947) .
Vol. 129 solved in VBS medium to 6 units/ml (as indicated by the manufacturer) if not otherwise stated.
Reptilase (Kramer, Lausanne, Switzerland) was used as obtained.
Human fibrinogen (Kabi, Stockholm, Sweden) was dissolved to a final concentration of 3.3mg/ml in 0.3M-NaCl in 28.5mM-veronal buffer, pH7.3, if not otherwise stated. A standard curve for the thrombinfibrinogen reaction was established with this fibrinogen concentration.
Preparation ofinhibitor
The 10OOOOg supernatants were prepared from perfused livers of starved male rats (Charles River, Wilmington, Mass., U.S.A., or Wistar/M011, Mollgaard, Havrup, Denmark). Each rat was given an intraperitoneal injection of warfarin [3-(Lx-acetonylbenzyl)-4-hydroxycoumarin; Marevan; Evans Medical Ltd., Speke, Liverpool, U.K.] (5mg/lOOg body wt.) 28 and 4h before being killed to decrease the amounts of vitamin K-dependent procoagulants (factors II, VII, IX and X) in the supernatants and thus prevent generation of thrombin. Supernatants from untreated rats gave similar results. The livers were perfused and washed with solution A (0.25M-sucrose-b mM-EDTA-35mM-tris-HCl, pH7.8) before being minced and homogenized in solution B (0.25M-sucrose-25mM-KCl-lOmM-MgCl2-35mM-tris-HCl, pH7.8). The homogenate was centrifuged at 1500g for 2-3 min and the supernatant was centrifuged at 100OOOg for 1 h. The I00OO0g supernatant was stored in 5ml portions at -20°C.
Three types of inhibitor preparations were used (type I, 1000OOg supernatant; type II, 1000OOg supernatant purified by filtration through Bio-Gel P-100; type III, 1000OOg supernatant purified by preparative disc electrophoresis).
Coagulation tests
These were performed at 37°C. The reagents were preincubated for 3min before addition of the final reagent unless otherwise stated.
The thromboplastin system contained: normal citrated human plasma, 0.1ml; VBS medium, 0.1 ml; tissue thromboplastin (Hjort, 1957) , 0.1 ml; 30mM-CaCl2, 0.1ml.
The thrombin-fibrinogen reaction system contained: fibrinogen solution, 0.2ml; VBS medium, 0.1 ml; thrombin solution, 0.1 ml.
The reptilase-fibrinogen reactionsystemcontained: fibrinogen solution (6.7mg/ml), 0.2ml; VBS medium, 0.1ml; 30mM-CaCl2, 0.1ml; reptilase (undiluted), 0.1ml.
Fibrin monomer was prepared essentially as described by Donnelly et al. (1955) . Fibrinogen was clotted once with thrombin and the clot was dissolved to a final concentration of 8.4mg/ml.
The fibrin-polymerization system contained: VBS medium, 0.1ml; 0.013M-glycine-NaOH buffer (pH 10.5), 0.1 ml; fibrin monomer solution (pH 5.3), 0.1ml.
The final pH in the reaction mixture was 7.5.
Inhibitor activity
This was tested by substituting inhibitor solutions for VBS medium in the above systems. Inhibitor solutions were always dialysed against VBS medium before testing. All dilutions for testing were done in this buffer. An inhibitor solution was considered to have 1 unit/ml when it decreased the activity of the standard thrombin solution by 0.06N.I.H. unit/ml in the thrombin test system described above.
Inhibition of thrombin was also tested with ptosyl-L-arginine methyl ester as substrate by incubating I ml of 0.1 M-p-tosyl-L-arginine methyl ester in 28.5mM-veronal buffer (Owren, 1947) Caseinolytic activity This was assayed as described by Jacobsen (1964) . Proteolytic activity was also tested by using ovalbumin, human albumin, azo-fibrinogen and azo-collagen as substrates in the same system, except that lysis ofthe azo-collagen was monitored at 520nm.
Anti-trypsin activity
This was investigated either by incubating 2ml of the various substrates for proteolysis with 0.2ml of trypsin solution (2.5mg/ml in VBS medium) and 0.2ml of inhibitor solution (type II), or with p-tosyl-L-arginine methyl ester as substrate for esterolysis: 3 ml oftrypsin solution 1 ml of0.2M-p-tosyl-L-arginine methyl ester in 0.15M-KCI, adjusted to pH7.0 with KOH, and 2.7ml of inhibitor (type II) were mixed and incubated at 37°C. The amount of 0.01 M-KOH used to titrate the mixture to pH 7.0 was measured by a Radiometer iTT l c pH-stat.
Other procedures
Preparative disc electrophoresis (Buchler Instruments, Fort Lee, N.J., U.S.A.), gel filtration (on BioGel P-100 (Bio-Rad, Richmond, Calif., U.S.A.) and Sepharose 4B (Pharmacia, Uppsala, Sweden)) and electrofocusing (LKB, Stockholm, Sweden) were carried out as described by the manufacturers. A slight modification of the method of Grossbach (1965) was used for analytical disc electrophoresis. Sodium dodecyl sulphate-polyacrylamide-gel electrophoresis was carried out as described by Glossmann & Lutz (1970) . Protein was determined by the method of Lowry et al. (1951) with bovine serum albumin (Sigma) as standard. All buffers were made from double-distilled water.
Results
In preliminary experiments the 1000OOg supernatant inhibited the coagulation of whole plasma with tissue thromboplastin as well as the thrombinfibrinogen reaction. The inhibitory activity was heatlabile and was recovered in the excluded fraction from Sephadex G-25. It was not adsorbed on BaSO4 or glass. The inhibitor of the thrombin-fibrinogen reaction was also found in supernatants from unperfused bovine liver. The 100OOg supernatant had considerable general proteolytic activity. Purified fractions (types II and III) had no proteolytic activity on any of the substrates tested and such preparations were used for the subsequent investigations.
1972 Purification of inhibitor Gel filtration. A Bio-Gel P-100 column (3cm x 55 cm) was equilibrated and eluted with VBS medium at a flow rate of about 20ml/h. The inhibitor was eluted just before haemoglobin. A 27-fold purification was obtained (Table 1) , probably partly due to removal of procoagulant material, which counteracted the inhibitor in the crude supematant. Such procoagulant material was recovered in later fractions.
Ammonium sulphateprecipitation. The inhibitor was precipitated at between 20 and 60% saturation. A slight purification was obtained (Table 1) .
Batch adsorption with CM-Sephadex. CM-Sephadex C-50 (Pharmacia) was equilibrated with 0.01 Msodium phosphate buffer, pH 6.5. Gel (3 ml) and 2ml of 100000g supernatant were stirred for 2h at 2°C. This left the inhibitor unadsorbed and gave about three-to-four-fold purification (Table 1) .
Precipitation at pH5.15. Equal volumes of 0.2M-sodium maleate buffer, pH 5.0, and inhibitor solution were mixed, giving pH 5.15. After precipitation and dialysis at 4°C the supernatant was tested for inhibitory activity. A twofold purification was obtained.
Preparative disc electrophoresis. This gave 800-1000-fold purification (Table 1 ). The inhibitor was eluted immediately before the tracking dye (Bromophenol Blue) . Preparations obtained after two successive runs gave one band in analytical disc electrophoresis at pH8.6 and had a specific activity of about 3100-3800units/mg of protein (Table 1) .
Physical characteristics ofthe purified inhibitor
From gel-filtration results a molecular weight of 70000-80000 was estimated. In sodium dodecyl sulphate-polyacrylamide-gel electrophoresis a single band with a molecular weight of 72000+3000 was observed. The pI was determined to be 3.50-3.75 by isoelectric focusing. The absorbance at 450nm excluded the presence of bilirubin, which has been Vol. 129 reported to exhibit antithrombin activity (Kopec et al., 1961) .
Stability
The main problem in purifying the inhibitor was its lability. The activity was fairly stable at 4°C for up to 20h in the range pH6.5-10, but decreased during longer dialysis and various other treatments. The activity was destroyed by heat (65°C/30min) and by p-hydroxymercuribenzoate (50,ug/ml) or 5,5'-dithiobis-(2-nitrobenzoic acid) (4.6mM). Ca2l and Mg2" (2mM) did not influence the inhibition, nor did they offer any protection.
Some protection of the inhibitory activity was observed with EDTA (2mM) and dithioerythritol (1 mM). EDTA is in itself an inhibitor of the thrombin-fibrinogen reaction (Godal, 1960; Bithell, 1964) . The activities of the liver inhibitor and EDTA were additive. The apparent protection of the inhibitor might be due to incomplete removal of EDTA in spite of extensive dialysis before testing.
Inhibitor activity
The purified inhibitor had no detectable antitrypsin activity and no proteolytic or esterolytic activity. The inhibitor did not progressively inhibit thrombin, as preincubation with thrombin or fibrinogen gave essentially the same inhibition and no increase compared with unincubated controls. No inhibition of the esterolytic activity of thrombin on p-tosyl-L-arginine methyl ester was found.
The inhibitor did not influence the reptilase time nor the polymerization of fibrin monomer induced by adjustment of pH in monomer solutions (Donnelly et al., 1955) .
We looked for complex-formation between inhibitor and fibrinogen by displacement of the peak of inhibitor when co-chromatographed with fibrinogen on Sepharose 4B (gel bed 3cmx39cm) in VBS medium, but no change was observed. The inhibitor was recovered in active form after the same elution volume as when it was chromatographed without fibrinogen.
In the tests for heparin cofactor activity a slight synergistic effect was obtained with heparin and inhibitor in preincubation with thrombin, whereas an antagonistic effect was observed in preincubation with fibrinogen (Table 2) .
Thrombin-fibrinogen reaction
The velocity of the thrombin-fibrinogen reaction was measured by the reciprocal value of the coagulation time, i.e. the sum of the time required for thrombin to build up a concentration of fibrin monomer sufficient to transform the solution into a gel (the enzyme phase: step I) and the time required for this transformation (the polymerization phase: step II). This measurement is probably valid with low thrombin concentration, i.e. when step I is ratelimiting. At thrombin concentrations above 1-2 units/ml (with 1-2mg of fibrinogen/ml) a plot of velocity versus thrombin concentration is no longer linear (Fig. 1) , probably because step II becomes ratelimiting. To secure a linear relation between thrombin concentration and reaction velocity (the inverse of coagulation time) in all kinetic studies the concentrations of thrombin and fibrinogen were between 0.75 and 1.0N.I.H. unit/ml and 0.125-3.3mg/ml respectively, if not otherwise indicated.
A saturation plateau was obtained in MichaelisMenten plots at fibrinogen concentrations of about 0.25-1.7mg/ml with 1 unit of thrombin/ml (Fig. 2) , whereas higher substrate concentrations gave a slight inhibition. Km for the thrombin-fibrinogen reaction was about 9.4 x 10-7 M.
Kinetics of inhibition
Maximum inhibition obtained with purified inhibitor was about 70% (Fig. 3) . In separate experiments purified inhibitor at a final concentration of 7.5,ug/ml decreased the thrombin activity by 40%. This inhibition was not overcome by increasing the thrombin concentration tenfold or the fibrinogen concentration fivefold. On the contrary, increasing inhibitor concentration (Fig. 5) . The hyperbolic plot was in accordance with the results obtained when complete inhibition of a small amount of thrombin was attempted. A plot of velocity versus thrombin concentration at various fixed inhibitor concentrations went through the origin (Fig. 6) . A slight change in Km was found. The inhibitor constant Kg was 2.5 x10-7 M, calculated from the Lineweaver-Burk plots. Discussion Previous workers have described various coagulation inhibitors obtained from liver (Fritz et al., 1968; Werle et al., 1967) . Deykin et al. (1969) found a competitive inhibitor of activated (by Russell's-viper venom) factor X in bovine liver. Their results also showed a marked inhibition of the thrombinfibrinogen reaction by the supernatant, but the two activities were partially separated by (NH4)2SO4 precipitation. Other substances in liver inhibiting proteases in general and thus also inhibiting blood coagulation (Fritz et al., 1967 (Fritz et al., , 1968 Werle et al., 1967) had a molecular weight of about 6500 and are clearly different from the inhibitor described here. To our knowledge a macromolecular inhibitor of the thrombin-fibrinogen reaction without general antiproteolytic activity has not been described from liver. The inhibitor is a heat-labile macromolecule with a molecular weight of about 72000 and a low isoelectric point (3.5-3.7). This may explain the migration ahead of the tracking dye in polyacrylamide-gel electrophoresis. Its activity can be observed with concentrations down to 1 ,ug/ml in a test system with 1 unit of thrombin/ml and 1 mg offibrinogen/ml. One or more thiol groups were necessary since 5,5'-dithiobis-(2-nitrobenzoic acid) and p-hydroxymercuribenzoate abolished and dithioerythritol protected the inhibitory activity. Oxidation of essential thiol groups may also at least partially explain the instability. No bivalent ions appeared necessary.
The inhibitor had no proteolytic nor anti-trypsin activity. Unlike antithrombin III, its effect on the thrombin-fibrinogen reaction was not time-dependent. In the presence of heparin a slight synergistic effect was observed, but much less than that found when heparin and anti-thrombin III were used (Abildgaard, 1968) . We therefore conclude that the inhibitor is different from the previously known macromolecular inhibitors of the thrombin-fibrinogen reaction, like anti-thrombin III, &2-macroglobulin and ax-trypsin inhibitor.
The kinetic study of inhibitor action in the thrombin-fibrinogen reaction necessitated a careful selection of thrombin and fibrinogen concentrations. Too little fibrinogen gave a reaction of higher than zero-order, too much fibrinogen gave substrate inhibition. Too much thrombin invalidated the velocity measurements, since step II (the polymerization Concn. of thrombin (N.I.H. unit/ml) Fig. 6 . Effect ofinhibitor at low thrombin concentration For experimental details see the text. The final concentration of fibrinogen was 0.51 mg/ml. o, Control; *, final concn. of inhibitor 3.5,ug/ml; A, final concn. of inhibitor 7,g/ml.
of fibrin monomer) became rate-limiting. Even with the appropriate concentrations the assumption that the coagulation time is a direct function of l/v is not proved. The kinetic data obtained will require confirmation by direct measurements of the velocity of the thrombin-fibrinogen reaction in the presence of inhibitor.
The Km for the thrombin-fibrinogen reaction was about 9.4x1O-M. Shinowara (1965) reported Km 4.38 x 10-7M for the reaction of human thrombin with human fibrinogen, and the slightly higher values reported here with bovine thrombin and human fibrinogen maybe due to the species difference. From the results of Blomback (1958) and Abildgaard (1967) on the appearance of N-terminal glycine, Km values of 0.9 x 10-5M and 0.8 x 1O-5M have been calculated. On the basis of the release of N-terminal glutamic acid with the A peptide of bovine fibrinogen, Blomback (1967) The inhibitor was non-competitive with respect to both enzyme and substrate. The inhibitor probably did not act on fibrinogen or fibrin, since it influenced neither polymerization nor reptilase time and no complex-formation with fibrinogen was detected. An effect on thrombin appears to be unlikely, since no inhibition of the esterolysis of p-tosyl-L-arginine methyl ester by thrombin was found, and increasing doses of thrombin did not overcome the inhibition.
Interaction of the inhibitor with the thrombinfibrinogen complex or the acylated thrombin intermediate remains the most likely mechanism. The inhibitor had a low pI and consequently a high negative charge at physiological pH values. In this respect it is similar to heparin, which also has been suggested to interact with the thrombin-fibrinogen conmplex (Abildgaard, 1968) . The absence of inhibition of the reptilase activity was another similarity.
The reaction did proceed in the presence of inhibitor, even when small doses of thrombin were used (Fig. 7) , indicating that the enzyme-substrateinhibitor complex broke down, but at a slower rate than the enzyme-substrate complex. For this type of non-competitive inhibition, the reciprocal plots do not intersect on the I/s axis; a hyperbolic curve is expected when the intercepts of double-reciprocal plots on their ordinates are plotted against the inhibitor concentration, and on increasing the substrate concentration increasing inhibition would be expected.
Such kinetics were observed for the present inhibitor (Figs. 4 and 5) . We conclude that the inhibitor probably interacted with the enzyme-substrate complex.
The physiological significance of this inhibitor remains unknown. Unexplained coagulation disturbances are known to occur in patients with liver disease. The presence of an inhibitor in human liver and plasma similar to that described here might contribute to such disturbances. Nothing is presently known about the influence of the inhibitor on the thrombin-induced platelet aggregation. B. 0. is a Stipendiate of the Norwegian Research Council for Science and the Humanities.
